A.R.T. Advisors’s Meridian Bioscience Inc VIVO Stock Holding History

A.R.T. Advisors’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-21,200	Closed	-$201K	–	1839
2019 Q3	$201K	Buy	+21,200	New	+$223K	0.01%	1185
2018 Q2	–	Sell	-29,400	Closed	-$417K	–	1860
2018 Q1	$417K	Buy	+29,400	New	+$435K	0.02%	1027
2017 Q4	–	Sell	-25,700	Closed	-$367K	–	1760
2017 Q3	$367K	Buy	+25,700	New	+$367K	0.02%	943
2016 Q3	–	Sell	-31,255	Closed	-$609K	–	1280
2016 Q2	$609K	Sell	31,255 -10,823	-26%	-$212K	0.03%	729
2016 Q1	$867K	Sell	42,078 -5,300	-11%	-$104K	0.04%	643
2015 Q4	$972K	Buy	47,378 +31,600	+200%	+$606K	0.05%	573
2015 Q3	$269K	Buy	15,778 +3,412	+28%	+$62.4K	0.01%	1072
2015 Q2	$230K	Buy	+12,366	New	+$229K	0.01%	1261
2014 Q2	–	Sell	-10,446	Closed	-$227K	–	1592
2014 Q1	$227K	Buy	10,446 +2,853	+38%	+$65.4K	0.01%	1110
2013 Q4	$201K	Buy	+7,593	New	+$187K	0.01%	1126

Other funds holding VIVO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SFM

Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

A.R.T. Advisors's VIVO Position: Q4 2019 in Review

A.R.T. Advisors sold out of Meridian Bioscience Inc (VIVO) in Q4 2019, closing a stake of 21,200 shares — an estimated $201K sold.

A.R.T. Advisors first reported a position in VIVO in Q4 2013 and held it in 10 quarters. The position peaked at $972K in Q4 2015. 170 funds tracked by Wall St. Rank hold VIVO as of Q4 2019.

A.R.T. Advisors reported no remaining Meridian Bioscience Inc position as of Q4 2019 after selling out during the quarter.
A.R.T. Advisors sold 21,200 Meridian Bioscience Inc shares in Q4 2019, an estimated $201K.
A.R.T. Advisors first reported a position in Meridian Bioscience Inc in Q4 2013 and held it in 10 quarters.
A.R.T. Advisors's Meridian Bioscience Inc position peaked at $972K in Q4 2015.
170 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q4 2019.

Based on A.R.T. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.